Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease (AERD).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Generic Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:CPIX
- CUSIP: 23077010
- Web: www.cumberlandpharma.com
Capitalization:- Market Cap: $112.7 million
- Outstanding Shares: 15,896,000
Average Prices:- 50 Day Moving Avg: $6.84
- 200 Day Moving Avg: $6.67
- 52 Week Range: $4.60 - $7.49
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 78.78
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $36.18 million
- Price / Sales: 3.12
- Book Value: $4.18 per share
- Price / Book: 1.70
Profitability:- EBIDTA: ($626,147.00)
- Net Margins: -19.57%
- Return on Equity: -0.13%
- Return on Assets: -0.11%
Debt:- Debt-to-Equity Ratio: 0.10%
- Current Ratio: 4.88%
- Quick Ratio: 4.45%
Misc:- Average Volume: 16,258 shs.
- Beta: 0.97
- Short Ratio: 4.88
Frequently Asked Questions for Cumberland Pharmaceuticals (NASDAQ:CPIX)
What is Cumberland Pharmaceuticals' stock symbol?
Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX."
How were Cumberland Pharmaceuticals' earnings last quarter?
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.07) earnings per share (EPS) for the quarter. The firm had revenue of $8.67 million for the quarter. Cumberland Pharmaceuticals had a negative net margin of 19.57% and a negative return on equity of 0.13%. View Cumberland Pharmaceuticals' Earnings History.
When will Cumberland Pharmaceuticals make its next earnings announcement?
Who are some of Cumberland Pharmaceuticals' key competitors?
Some companies that are related to Cumberland Pharmaceuticals include Fortress Biotech (FBIO), Ovid Therapeutc (OVID), Organovo Holdings (ONVO), Foamix Pharmaceuticals (FOMX), MannKind Corporation (MNKD), Mast Therapeutics (SVRA), ObsEva SA (OBSV), uniQure N.V. (QURE), Kindred Biosciences (KIN), Catalyst Pharmaceuticals (CPRX), Vital Therapies (VTL), Nymox Pharmaceutical Corporation (NYMX), Advaxis (ADXS), Verastem (VSTM), Cascadian Therapeutics (CASC), Biodel (ALBO), Vascular Biogenics (VBLT) and Spring Bank Pharmaceuticals (SBPH).
Who are Cumberland Pharmaceuticals' key executives?
Cumberland Pharmaceuticals' management team includes the folowing people:
- A. J. Kazimi, Chairman of the Board, Principal Executive Officer
- Michael Bonner, Senior Director Finance and Accounting and Chief Financial Officer
- Martin E. Cearnal, Senior Vice President, Chief Commercial Officer, Director
- Leo Pavliv, Senior Vice President - Operations, Chief Development Officer
- James L. Herman, Vice President - National Accounts, Chief Compliance Officer
- Amy Dix Rock Ph.D., Vice President - Regulatory & Scientific Affairs
- Gordon R. Bernard M.D., Independent Director
- Jonathan Griggs, Independent Director
- Joey A. Jacobs, Independent Director
- James R Jones, Independent Director
Who owns Cumberland Pharmaceuticals stock?
Cumberland Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (6.92%), Dimensional Fund Advisors LP (5.40%), Vanguard Group Inc. (1.86%), New York State Common Retirement Fund (1.68%), JW Asset Management LLC (1.65%) and Acadian Asset Management LLC (0.81%). Company insiders that own Cumberland Pharmaceuticals stock include Michael Bonner and Thomas R Lawrence. View Institutional Ownership Trends for Cumberland Pharmaceuticals.
Who sold Cumberland Pharmaceuticals stock? Who is selling Cumberland Pharmaceuticals stock?
Who bought Cumberland Pharmaceuticals stock? Who is buying Cumberland Pharmaceuticals stock?
Cumberland Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Essex Investment Management Co. LLC, Dimensional Fund Advisors LP, Vanguard Group Inc. and Ameriprise Financial Inc.. View Insider Buying and Selling for Cumberland Pharmaceuticals.
How do I buy Cumberland Pharmaceuticals stock?
Shares of Cumberland Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cumberland Pharmaceuticals' stock price today?
One share of Cumberland Pharmaceuticals stock can currently be purchased for approximately $7.09.
MarketBeat Community Rating for Cumberland Pharmaceuticals (NASDAQ CPIX)MarketBeat's community ratings are surveys of what our community members think about Cumberland Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cumberland Pharmaceuticals (NASDAQ:CPIX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Cumberland Pharmaceuticals (NASDAQ:CPIX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Cumberland Pharmaceuticals (NASDAQ:CPIX)Earnings History by Quarter for Cumberland Pharmaceuticals (NASDAQ CPIX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/30/2017 | | | | | | | N/A |  |
| 8/8/2017 | Q2 2017 | | ($0.07) | | $8.67 million | View | Listen | |
| 5/15/2017 | Q1 2017 | | ($0.08) | | $9.64 million | View | N/A | |
| 3/7/2017 | Q4 2016 | | $0.05 | | $9.08 million | View | Listen | |
| 11/1/2016 | Q316 | | $0.01 | $7.90 million | $8.80 million | View | N/A | |
| 5/10/2016 | Q116 | | $0.02 | $8.70 million | $7.70 million | View | Listen | |
| 5/7/2015 | Q115 | | $0.09 | $8.10 million | $8.70 million | View | N/A | |
| 5/13/2014 | Q114 | | $0.02 | $10.26 million | $8.09 million | View | N/A | |
| 3/4/2014 | Q4 13 | $0.05 | ($0.08) | | | View | N/A | |
| 11/5/2013 | Q313 | | ($0.04) | $7.60 million | $6.50 million | View | N/A | |
| 8/6/2013 | Q2 2013 | $0.02 | ($0.03) | $9.40 million | $7.10 million | View | N/A | |
| 5/2/2013 | Q113 | $0.05 | $0.05 | $10.00 million | $10.30 million | View | N/A | |
| 2/28/2013 | Q4 2012 | $0.14 | $0.09 | $13.87 million | $13.70 million | View | N/A | |
| 11/1/2012 | Q312 | $0.09 | $0.10 | $13.05 million | $12.50 million | View | N/A | |
| 8/2/2012 | | $0.07 | $0.09 | | | View | N/A | |
| 5/3/2012 | | $0.05 | $0.02 | | | View | N/A | |
| 2/29/2012 | | $0.05 | $0.04 | | | View | N/A | |
| 11/3/2011 | | $0.06 | $0.09 | | | View | N/A | |
| 8/4/2011 | | $0.04 | $0.11 | | | View | N/A | |
| 5/5/2011 | | $0.03 | $0.03 | | | View | N/A | |
| 3/8/2011 | | $0.03 | $0.04 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cumberland Pharmaceuticals (NASDAQ:CPIX)Current Year EPS Consensus Estimate: $0.09 EPS
Next Year EPS Consensus Estimate: $0.09 EPS
Dividend History for Cumberland Pharmaceuticals (NASDAQ:CPIX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cumberland Pharmaceuticals (NASDAQ:CPIX)Insider Ownership Percentage: 38.00%
Institutional Ownership Percentage: 34.30%
Insider Trades by Quarter for Cumberland Pharmaceuticals (NASDAQ:CPIX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/23/2017 | Michael Bonner | CFO | Buy | 500 | $6.72 | $3,360.00 | |
| 5/31/2017 | Michael Bonner | CFO | Buy | 300 | $6.95 | $2,085.00 | |
| 4/7/2017 | Thomas R. Lawrence | Director | Sell | 6,000 | $6.40 | $38,400.00 | |
| 3/23/2017 | Michael Bonner | CFO | Buy | 900 | $6.42 | $5,778.00 | |
| 11/17/2016 | Michael Bonner | CFO | Buy | 900 | $5.50 | $4,950.00 | |
| 8/17/2016 | Thomas R Lawrence | Director | Sell | 3,000 | $4.60 | $13,800.00 | |
| 5/26/2016 | Thomas R Lawrence | Director | Sell | 3,000 | $4.55 | $13,650.00 | |
| 11/19/2015 | Thomas R Lawrence | Director | Sell | 4,000 | $5.61 | $22,440.00 | |
| 3/19/2015 | Thomas R Lawrence | Director | Sell | 6,000 | $6.95 | $41,700.00 | |
| 11/20/2014 | Thomas R Lawrence | Director | Sell | 10,000 | $5.12 | $51,200.00 | |
| 8/21/2014 | Thomas R Lawrence | Director | Sell | 15,000 | $5.08 | $76,200.00 | |
| 3/19/2014 | Thomas Lawrence | Director | Sell | 20,000 | $4.54 | $90,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cumberland Pharmaceuticals (NASDAQ:CPIX)
Latest Headlines for Cumberland Pharmaceuticals (NASDAQ:CPIX)
| Source: |
|
| Date | Headline |
|---|
 | What Are The Drivers Of Cumberland Pharmaceuticals Inc’s (CPIX) Risks?
finance.yahoo.com - September 13 at 6:41 PM |
| Edited Transcript of CPIX earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 12 at 3:55 AM |
| Cumberland reports 2Q loss
finance.yahoo.com - August 8 at 10:15 PM |
 | Cumberland Pharmaceuticals Inc. (CPIX) Releases Earnings Results
www.americanbankingnews.com - August 8 at 9:30 PM |
| Cumberland Pharmaceutical Reports Double Digit Revenue Growth For The Fourth Consecutive Quarter
finance.yahoo.com - August 8 at 5:13 PM |
| Cumberland Pharmaceuticals Inc. (CPIX) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 3 at 10:40 AM |
| Cumberland Pharmaceuticals To Announce Second Quarter 2017 Financial Results
finance.yahoo.com - August 1 at 6:08 PM |
| Cumberland Pharmaceuticals Begin U.S. Shipments Of Dexrazoxane For Oncology Patient Support
finance.yahoo.com - July 31 at 5:23 PM |
| Cumberland Pharmaceuticals Inc. (CPIX) Set to Announce Earnings on Monday
www.americanbankingnews.com - July 24 at 8:49 AM |
| Financial Contrast: Cumberland Pharmaceuticals (NASDAQ:CPIX) and Merus Labs International (MSLI)
www.americanbankingnews.com - July 17 at 10:27 AM |
| ETFs with exposure to Cumberland Pharmaceuticals, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 6:10 PM |
| Head-To-Head Survey: Cumberland Pharmaceuticals (CPIX) & Merus Labs International (MSLI)
www.americanbankingnews.com - June 22 at 12:20 AM |
| ETFs with exposure to Cumberland Pharmaceuticals, Inc. : May 25, 2017
finance.yahoo.com - May 25 at 6:02 PM |
| Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 4:18 PM |
| Cumberland Pharmaceuticals, Inc. (CPIX) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 16 at 2:20 PM |
| Edited Transcript of CPIX earnings conference call or presentation 15-May-17 8:30pm GMT
finance.yahoo.com - May 16 at 12:16 PM |
| Investor Network: Cumberland Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - May 15 at 4:23 PM |
| Investor Network: Cumberland Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - May 15 at 4:23 PM |
| Cumberland Pharmaceuticals Reports Revenue Growth Of 25% In First Quarter 2017
finance.yahoo.com - May 15 at 4:23 PM |
| Cumberland Pharmaceuticals Reports Revenue Growth Of 25% In First Quarter 2017
finance.yahoo.com - May 15 at 4:23 PM |
| Cumberland Pharmaceuticals to Announce First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 4:21 PM |
| Cumberland Pharmaceuticals (CPIX) Getting Somewhat Positive News Coverage, AlphaOne Reports
www.americanbankingnews.com - May 1 at 6:28 PM |
| Cumberland Pharmaceuticals, Inc. (CPIX) Short Interest Up 26.3% in April
www.americanbankingnews.com - April 29 at 11:56 PM |
| Cumberland Pharmaceuticals (CPIX) Given Daily Media Sentiment Rating of 0.36
www.americanbankingnews.com - April 27 at 10:30 AM |
| New Kristalose® Growth Driver Established Through Co-Promotion Agreement
finance.yahoo.com - April 26 at 5:52 PM |
| Cumberland Pharmaceuticals (CPIX) Getting Somewhat Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 23 at 5:06 PM |
| Thomas R. Lawrence Sells 6,000 Shares of Cumberland Pharmaceuticals, Inc. (CPIX) Stock
www.americanbankingnews.com - April 7 at 8:28 PM |
 | Cumberland Pharmaceuticals (CPIX) Reports Significant Post Surgical Pain Reduction and Decrease in Opioid Use from Caldolor®
www.streetinsider.com - March 28 at 4:14 PM |
| Caldolor® Demonstrates Significant Post Surgical Pain Reduction and Decrease in Opioid Use
finance.yahoo.com - March 27 at 4:22 PM |
| CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K/A, Changes in Registrant's Certifying Accountant, Financial Stateme
biz.yahoo.com - March 22 at 9:35 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cumberland Pharmaceuticals Inc.
finance.yahoo.com - March 22 at 4:35 PM |
 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cumberland ...
www.businesswire.com - March 18 at 1:56 AM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cumberland Pharmaceuticals Inc.
finance.yahoo.com - March 17 at 3:54 PM |
| CUMBERLAND PHARMACEUTICALS INC Financials
finance.yahoo.com - March 16 at 5:49 PM |
| CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant
biz.yahoo.com - March 16 at 5:49 PM |
| CUMBERLAND PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 13 at 12:28 PM |
| CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 10 at 5:32 PM |
| Edited Transcript of CPIX earnings conference call or presentation 7-Mar-17 9:30pm GMT
finance.yahoo.com - March 8 at 5:12 PM |
| Cumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results
finance.yahoo.com - March 7 at 4:26 PM |
| Q4 2016 Cumberland Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - March 7 at 12:16 PM |
| Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2016 Financial Results
finance.yahoo.com - February 28 at 4:39 PM |
 | Caldolor® Pediatric Fever Study Published Supporting Its Efficacy, Safety And Pharmacokinetics
www.prnewswire.com - February 7 at 5:35 PM |
| Caldolor® Pediatric Fever Study Published Supporting Its Efficacy, Safety And Pharmacokinetics
www.prnewswire.com - February 7 at 5:35 PM |
 | U.S. Court Of Appeals Affirms Cumberland Pharmaceuticals' Victory In Patent Litigation Case
us.rd.yahoo.com - January 30 at 5:19 PM |
| 8:17 am Cumberland Pharma announces the U.S. Court of Appeals for the Federal Circuit ruled in favor of Cumberland in a patent case associated with its Acetadote product, rejecting Mylan's (MYL) challenge o
us.rd.yahoo.com - January 30 at 5:19 PM |
| Cumberland Pharmaceuticals Announces Kenneth J. Krogulski To Join Its Board Of Directors
finance.yahoo.com - January 16 at 10:28 AM |
| CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events
biz.yahoo.com - January 13 at 5:11 PM |
| Cumberland Pharmaceuticals (CPIX), Clinigen Enter Pact for Commercialization of Totect
www.streetinsider.com - January 9 at 10:37 PM |
| 9:31 am Cumberland Pharma and and Clinigen Group plc announce an exclusive agreement to commercialize the oncology support drug Totect (dexrazoxane hydrochloride) in the U.S.
finance.yahoo.com - January 9 at 5:37 PM |
| Blog Coverage Cumberland Pharma Bags Exclusive Rights for Europe Based Nordic Group Injectable Methotrexate Product Line for the US Market
finance.yahoo.com - November 17 at 10:16 AM |
Cumberland Pharmaceuticals (CPIX) Chart for Tuesday, September, 19, 2017
